Latent Raises $80M Series A to Rebuild Medication Access with Clinical AI

Healthcare runs on precision, but access to medication still runs on delay. Not because the science is lacking, but because the system drags its feet in all the wrong places. Between diagnosis and treatment sits a maze of approvals, paperwork, and back and forth that quietly dictates outcomes. That stretch of time is not just inefficient, it is expensive, fragile, and in some cases, unforgiving. That is the lane Latent chose to own.

Latent just pulled in $80M in Series A funding out of San Francisco, with Spark Capital and Transformation Capital leading the charge, backed by Conviction, McKesson Ventures, General Catalyst, and Y Combinator. That is not just a cap table. That is a coalition betting that the most valuable move in healthcare is not another app or dashboard, but removing friction where it quietly hurts the most.

Rishabh Jain, CEO, and Sriram Somasundaram, CTO, are not chasing noise. They are targeting the choke point. Latent’s clinical AI steps into the messy middle, reading EHR data, interpreting payer requirements, assembling documentation, and pushing prior authorizations forward without the usual phone and fax theater. It is less about replacing humans and more about giving them their time back while patients get what they need before “urgent” turns into “too late.”

And here is where it gets interesting. Latent is already working with 50% of the top 20 health systems in the U.S. That is not early hype. That is distribution where it counts. When systems at that scale lean in, it usually means the product is not just clever, it works under pressure.

The name “Latent” does a little double duty. In machine learning, it is what sits beneath the surface, patterns waiting to be unlocked. In healthcare, it is the delay no one wants to talk about. The company is playing both sides of that definition, pulling hidden signal out of clinical data while squeezing out the invisible lag that slows everything down.

What stands out in this round is not just the capital, it is the alignment. You have investors who understand infrastructure, healthcare complexity, and data gravity all circling the same thesis. Fix the access layer and everything downstream moves faster.

There is a lesson here for builders. The obvious problems get attention. The painful ones get funded. Latent went straight for the operational choke point and turned it into a product. No theatrics, just leverage. Healthcare does not need more noise. It needs fewer delays. And right now, Latent is making time the variable they control.